Filing Flows › Xilio Therapeutics (XLO) › Q4 2024
Xilio Therapeutics (XLO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 11, 2025
Xilio Therapeutics (XLO) reported revenue of $1.7M for the fourth quarter 2024 (Q4 2024) and -24% from the quarter before. Operating margin was -790.5%, net loss $13.1M (759.5% of revenue).
Xilio Therapeutics, Q4 2024: revenue $1.7M, operating margin -790.5%, net loss $13.1M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | -24% | — |
| Operating profit | −$13.6M | — | — |
| Net earnings | −$13.1M | — | — |
| Operating cash flow | −$14.2M | — | — |
What changed
Revenue was $1.7M in Q4 2024, down 24% from the previous quarter.
Operating costs exceeded revenue by $13.6M, an operating margin of -790.5%. The quarter ended with a net loss of $13.1M, narrower than the previous quarter's $14.0M loss.
Operating cash flow was −$14.2M. Non-cash charges added back $376K of depreciation and amortization and $1.5M of share-based compensation. Working capital and other items used $3.0M. Capital expenditures of $6K exceeded it, leaving free cash flow of −$14.2M.
Questions
What was Xilio Therapeutics' revenue in the fourth quarter 2024?
Xilio Therapeutics (XLO) reported revenue of $1.7M for the fourth quarter 2024 (Q4 2024) and -24% from the quarter before.
Was Xilio Therapeutics profitable in the fourth quarter 2024?
Operating loss was $13.6M (-790.5% of revenue) and net loss $13.1M.
Source: Xilio Therapeutics 10-K on SEC EDGAR.